Abbott

YTD

ALL

Trade Abbott 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

CEO

Robert B. Ford

CEORobert B. Ford

Employees

115,000

Employees115,000

Headquarters

Abbott Park, Illinois

HeadquartersAbbott Park, Illinois

Founded

1888

Founded1888

Employees

115,000

Employees115,000

ABT Key Statistics

Market cap

154.83B

Market cap154.83B

Price-Earnings ratio

24.78

Price-Earnings ratio24.78

Dividend yield

2.74%

Dividend yield2.74%

Average volume

10.97M

Average volume10.97M

High today

$89.88

High today$89.88

Low today

$87.64

Low today$87.64

Open price

$87.99

Open price$87.99

Volume

7.81M

Volume7.81M

52 Week high

$137.49

52 Week high$137.49

52 Week low

$81.97

52 Week low$81.97

Stock Snapshot

As of today, Abbott(ABT) shares are valued at $88.89. The company's market cap stands at 154.83B, with a P/E ratio of 24.78 and a dividend yield of 2.74%.

During the trading session on 2026-07-15, Abbott(ABT) shares reached a daily high of $89.88 and a low of $87.64. At a current price of $88.89, the stock is +1.4% higher than the low and still -1.1% under the high.

Trading activity shows a volume of 7.81M, compared to an average daily volume of 10.97M.

Over the past 52 weeks, Abbott(ABT) stock has traded between a high of $137.49 and a low of $81.97.

ABT News

Seeking Alpha 3h

Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

Abbott Laboratories (ABT) is due to report second-quarter earnings on July 15, with analysts expecting the firm to report healthy top- and bottom-line growth....

Simply Wall St 13h

Can Abbott Turn Freenome Progress Into a Durable Diagnostics-Led Growth Story?

Abbott Laboratories is preparing to report its second-quarter 2026 results after a period of advances in diagnostics and medical devices, including its cancer-f...

Simply Wall St 5d

Abbott Stock Still Looks Cheap On Cash Flow And Earnings

Abbott Laboratories stock has fallen about 27.4% over the past year, yet both its intrinsic value estimate using a Discounted Cash Flow (DCF) approach and the m...

Analyst ratings

83%

of 29 ratings

Buy

82.8%

Hold

17.2%

Sell

More ABT News

The Motley Fool 7d

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?

Should you stick with a diversified healthcare titan or a specialized high-growth challenger? Here is how Abbott Laboratories (ABT 0.70%) and Glaukos (GKOS +1.5...

People also own

Based on the portfolios of people who own ABT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.